Literature DB >> 10576007

Following the clues to neuropathic pain. Distribution and other leads reveal the cause and the treatment approach.

M J Belgrade1.   

Abstract

Neuropathic pain can seem enigmatic at first because it can last indefinitely and often a cause is not evident. However, heightened awareness of typical characteristics, such as the following, makes identification fairly easy: The presence of certain accompanying conditions (e.g., diabetes, HIV or herpes zoster infection, multiple sclerosis) Pain described as shooting, stabbing, lancinating, burning, or searing Pain worse at night Pain following anatomic nerve distribution Pain in a numb or insensate site The presence of allodynia Neuropathic pain responds poorly to standard pain therapies and usually requires specialized medications (e.g., anticonvulsants, tricyclic antidepressants, opioid analgesics) for optimal control. Successful pain control is enhanced with use of a systematic approach consisting of disease modification, local or regional measures, and systemic therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10576007     DOI: 10.3810/pgm.1999.11.770

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  7 in total

Review 1.  Flupirtine in pain management: pharmacological properties and clinical use.

Authors:  Jacques Devulder
Journal:  CNS Drugs       Date:  2010-10       Impact factor: 5.749

Review 2.  The Circadian Clocks, Oscillations of Pain-Related Mediators, and Pain.

Authors:  Wenguo Fan; Fang Huang; Yanhao Chu; Hongwen He; Qing Liu; Shilin Jia
Journal:  Cell Mol Neurobiol       Date:  2022-02-18       Impact factor: 5.046

3.  Once-daily gastroretentive gabapentin for the management of postherpetic neuralgia: an update for clinicians.

Authors:  Gordon Irving
Journal:  Ther Adv Chronic Dis       Date:  2012-09       Impact factor: 5.091

Review 4.  Efficacy of pregabalin and gabapentin for neuropathic pain in spinal-cord injury: an evidence-based evaluation of the literature.

Authors:  Thrasivoulos G Tzellos; Georgios Papazisis; Ekaterini Amaniti; Dimitrios Kouvelas
Journal:  Eur J Clin Pharmacol       Date:  2008-07-08       Impact factor: 2.953

5.  Efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: interim analysis from an open-label, two-stage adaptive, randomized, controlled trial.

Authors:  Ralf Baron; Victor Mayoral; Göran Leijon; Andreas Binder; Ilona Steigerwald; Michael Serpell
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

6.  Predictors of new-onset distal neuropathic pain in HIV-infected individuals in the era of combination antiretroviral therapy.

Authors:  Jemily Malvar; Florin Vaida; Chelsea Fitzsimons Sanders; J Hampton Atkinson; William Bohannon; John Keltner; Jessica Robinson-Papp; David M Simpson; Christina M Marra; David B Clifford; Benjamin Gelman; Juanjuan Fan; Igor Grant; Ronald J Ellis
Journal:  Pain       Date:  2015-04       Impact factor: 7.926

7.  Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin.

Authors:  Neel Mehta; Iwona Bucior; Shay Bujanover; Rajiv Shah; Amitabh Gulati
Journal:  Health Qual Life Outcomes       Date:  2016-04-01       Impact factor: 3.186

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.